PUSH THE BOUNDS OF SCIENCE
Making new medicines for people with serious diseases
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Watch what drives us
Regeneron by the numbers
35+
years of scientific leadership
13.4K+
employees worldwide across 12 countries
12
medicines approved in the U.S. and/or other countries
35+
product candidates in clinical development across multiple therapeutic areas
~60
countries with Regeneron clinical trials
200+
global and U.S. patient advocacy and professional societies engaged across 40+ diseases
Top 10%
ranking in biotech industry across 3 leading environmental, social and governance (ESG) ratings
Technology for now and the future
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies.
We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
Doing well by doing good
Through responsible business practices and with the highest standards of integrity, we rise to any challenge with our characteristic drive and science-led approach. Our 2025 responsibility goals support the United Nations Sustainable Development Goals (SDGs) and span our three strategic focus areas:
Improving the lives of people
with serious diseases
Fostering a culture of
integrity and excellence
Building sustainable
communities
We are proud of the rankings and recognitions we have received for our corporate responsibility leadership and efforts.
- S&P Global: Top 1% in the biotechnology industry; Member: Dow Jones Sustainability Index World and North America, 2023
- Sustainalytics: Top 2% in biotechnology industry
- MSCI: A (ESG Rating, as of April 2023)
- FTSE4Good: 3.9 score; Member: FTSE4Good Index Series
- ISS-ESG: B-, (ESG Corporate Rating)
- Eight consecutive years on Civic 50 list of the most community-minded companies in the U.S.
- Best Community Partnership with Society for Science by Scrip for Regeneron Science Talent Search
- Newsweek: America’s Most Responsible Companies, 2023
- Biospace: Best Place to Work, 2023
- Glassdoor: Best Places to Work, 2023
- Newsweek: America’s Greatest Workplaces for Diversity, 2023
- Science: Top Employer, 2023